Evidence map›Paper›PMID 33743624›Full record

ArticleBMC infectious diseases2021

Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.

Caroline Bartolo, Victoria Hall, N Deborah Friedman, Chloe Lanyon, Andrew Fuller, C Orla Morrissey, Eugene Athan

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Isolation ofJournal of fungi (Basel, Switzerland) · 2024
    Article
  5. Isolated renal aspergilloma.Urology case reports · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Drug-induced normoglycemic candidal balanoposthitis: A case series.Indian journal of sexually transmitted diseases and AIDS
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Caroline BartoloDepartment of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia. caroline.bartolo@barwonhealth.org.au.ORCID http://orcid.org/0000-0001-8258-414X
Victoria HallDepartment of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia. victoria.hall@uhn.ca.
N Deborah FriedmanDepartment of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia.
Chloe LanyonDepartment of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia.
Andrew FullerDepartment of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia.
C Orla MorrisseyDepartment of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia.
Eugene AthanDepartment of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia.
Barwon Health · AUThe Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor. CASE PRESENTATIONS: Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with Candida albicans balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with Candida glabrata candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased.

conclusionsDespite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.

Indexed as

AgedBenzhydryl CompoundsCandidiasisDiabetes Mellitus, Type 2GlucosidesGlycosuriaHumansHypoglycemic AgentsMaleMiddle AgedPharmaceutical PreparationsSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesHypoglycemic AgentsPharmaceutical PreparationsSodium-Glucose Transporter 2 InhibitorsCandidemiaCase reportGenital mycotic infectionGlycosuriaProstatic abscessSGLT2 inhibitor

Identifiers

PMID33743624
PMCPMC7980614
OpenAlexW3139376628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.